Univariate analysis pLQ vs other* | P values | OR | 95% CI |
Female sex | 0.002 | 0.34 | 0.17 to 0.68 |
Age >40 years | 0.51 | 1.19 | 0.70 to 2.03 |
Disease duration† | 0.57 | 1.01 | 0.97 to 1.05 |
African American | <0.001 | 0.23 | 0.11 to 0.49 |
Years of education >12 years | 0.01 | 2.28 | 1.21 to 4.28 |
Income $ | |||
<30 000 | ref | ||
30 000–65 000 | 0.47 | 1.34 | 0.61 to 2.90 |
≥65 000 | 0.007 | 2.56 | 1.29 to 5.08 |
Smoking at baseline | 0.08 | 0.39 | 0.14 to 1.10 |
SLEDAI baseline† | <0.001 | 0.62 | 0.52 to 0.73 |
PGA baseline† | <0.001 | 0.26 | 0.16 to 0.44 |
Immunosuppressive drug treatment | |||
1. Ever received | 0.007 | 0.46 | 0.26 to 0.81 |
2. ≥75% of visits | 0.46 | 0.79 | 0.43 to 1.47 |
Hydroxychloroquine | |||
1. Ever received | 0.47 | 0.80 | 0.44 to 1.46 |
2. ≥75% of visits | 0.20 | 1.45 | 0.82 to 2.54 |
Prednisone | |||
1. Ever received | 0.02 | 0.53 | 0.31 to 0.91 |
2. ≥75% of visits | 0.002 | 0.40 | 0.23 to 0.71 |
*pLQ: n:59, other: pCA, pRR and mixed: n:857.
†per unit.
pCA, persistent chronic active; PGA, physician’s global assessment; pLQ, persistent long quiescent; pRR, persistent relapsing remitting; SLE, systemic lupus erythematosus; SLEDAI, SLE Disease Activity Index.